Search

Your search keyword '"Jang, Tae-Won"' showing total 440 results

Search Constraints

Start Over You searched for: Author "Jang, Tae-Won" Remove constraint Author: "Jang, Tae-Won"
440 results on '"Jang, Tae-Won"'

Search Results

2. Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database

8. Investigating treatment response and immune profile in association with pattern identification in NSCLC patients scheduled for immune checkpoint inhibitor monotherapy (HARMONY study): A protocol for a prospective observational study

13. Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea

14. Trend of prevalence and characteristics of preserved ratio impaired spirometry (PRISm): Nationwide population-based survey between 2010 and 2019.

16. Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data

17. Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study

18. Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial

19. Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors

20. Recommendation of Pharmacokinetics/Pharmacodynamics Target of Ethambutol to Suppress Tuberculosis Resistance: A Population Pharmacokinetics Study on Large Prospective Cohort

21. Abstract 3886: Analysis of concomitant genetic alterations in advanced EGFR-mutated lung adenocarcinoma by targeted NGS: A multicenter prospective and real world study

23. Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer

30. Improved Adaptive Modulation and Coding of MIMO with Selection Transmit Diversity Systems

33. A phase II , multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable,EGFRmutation‐positive non‐small cell lung cancer (stage III ) who have not progressed following definitive, platinum‐based, chemoradiation therapy ( PLATINUM trial)

36. Performance Limitation of STBC OFDM-CDMA Systems in Mobile Fading Channels

39. Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial

40. Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment

42. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea

48. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)

Catalog

Books, media, physical & digital resources